FAM168B

Across TCGA pan-cancer cohorts, FAM168B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM168B data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FAM168B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FAM168B expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, GBM, and LSCC are the cancer types where FAM168B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.858	0.599	.002	14	view →
GBM	OS	Median	All	0.472	0.289	.009	12	view →
LSCC	OS	Median	All	1.000	0.939	.014	7	view →
CCRCC	DFS	Median	IV	0.887	0.198	.024	6	view →
UCEC	OS	Quartile	III,IV	0.288	1.000	.040	4	view →
PDAC	OS	Median	IV	0.293	0.916	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM168B–HNSC (OS)

Open the HNSC breakdown →